NOCIL Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: August 8, 2025, 5:28 pm

Quick Insight

NOCIL Ltd, operating in the petrochemicals-polymers sector, displays a price of ₹185 with a market capitalization of ₹3,085 Cr. The company's P/E ratio stands at 30.0, indicating a relatively high valuation compared to industry peers. Despite a ROE of 5.94% and ROCE of 6.65%, the OPM at 10% suggests room for improvement in operational efficiency. With a healthy ICR of 94.70x and a moderate P/BV ratio of 1.66x, NOCIL shows stability and decent asset backing. The company's CCC at 133 days warrants attention for potential working capital management enhancements. In conclusion, while NOCIL exhibits strengths in financial health and investor distribution, focus on operational margins and working capital efficiency could be key areas for future growth and value creation.

Competitors of NOCIL Ltd

All Competitor Stocks of NOCIL Ltd

Quarterly Result

Last Updated: May 31, 2025, 8:16 am

Below is a detailed analysis of the quarterly data for NOCIL Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Sales, as of Mar 2025, the value is 340.00 Cr.. The value appears strong and on an upward trend. It has increased from 318.00 Cr. (Dec 2024) to 340.00 Cr., marking an increase of 22.00 Cr..
• For Expenses, as of Mar 2025, the value is 305.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 294.00 Cr. (Dec 2024) to 305.00 Cr., marking an increase of 11.00 Cr..
• For Operating Profit, as of Mar 2025, the value is 34.00 Cr.. The value appears strong and on an upward trend. It has increased from 24.00 Cr. (Dec 2024) to 34.00 Cr., marking an increase of 10.00 Cr..
• For OPM %, as of Mar 2025, the value is 10.00%. The value appears strong and on an upward trend. It has increased from 8.00% (Dec 2024) to 10.00%, marking an increase of 2.00%.
• For Other Income, as of Mar 2025, the value is 6.00 Cr.. The value appears to be declining and may need further review. It has decreased from 9.00 Cr. (Dec 2024) to 6.00 Cr., marking a decrease of 3.00 Cr..
• For Interest, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 0.00 Cr..
• For Depreciation, as of Mar 2025, the value is 13.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 14.00 Cr. (Dec 2024) to 13.00 Cr., marking a decrease of 1.00 Cr..
• For Profit before tax, as of Mar 2025, the value is 26.00 Cr.. The value appears strong and on an upward trend. It has increased from 19.00 Cr. (Dec 2024) to 26.00 Cr., marking an increase of 7.00 Cr..
• For Tax %, as of Mar 2025, the value is 20.00%. The value appears to be improving (decreasing) as expected. It has decreased from 32.00% (Dec 2024) to 20.00%, marking a decrease of 12.00%.
• For Net Profit, as of Mar 2025, the value is 21.00 Cr.. The value appears strong and on an upward trend. It has increased from 13.00 Cr. (Dec 2024) to 21.00 Cr., marking an increase of 8.00 Cr..
• For EPS in Rs, as of Mar 2025, the value is 1.24. The value appears strong and on an upward trend. It has increased from 0.77 (Dec 2024) to 1.24, marking an increase of 0.47.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 4:37 pm

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: June 16, 2025, 11:37 am

Below is a detailed analysis of the balance sheet data for NOCIL Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 167.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 167.00 Cr..
• For Reserves, as of Mar 2025, the value is 1,595.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,532.00 Cr. (Mar 2024) to 1,595.00 Cr., marking an increase of 63.00 Cr..
• For Borrowings, as of Mar 2025, the value is 10.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 13.00 Cr. (Mar 2024) to 10.00 Cr., marking a decrease of 3.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 284.00 Cr.. The value appears to be improving (decreasing). It has decreased from 304.00 Cr. (Mar 2024) to 284.00 Cr., marking a decrease of 20.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 2,057.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,015.00 Cr. (Mar 2024) to 2,057.00 Cr., marking an increase of 42.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 855.00 Cr.. The value appears to be declining and may need further review. It has decreased from 870.00 Cr. (Mar 2024) to 855.00 Cr., marking a decrease of 15.00 Cr..
• For CWIP, as of Mar 2025, the value is 60.00 Cr.. The value appears strong and on an upward trend. It has increased from 16.00 Cr. (Mar 2024) to 60.00 Cr., marking an increase of 44.00 Cr..
• For Investments, as of Mar 2025, the value is 366.00 Cr.. The value appears to be declining and may need further review. It has decreased from 399.00 Cr. (Mar 2024) to 366.00 Cr., marking a decrease of 33.00 Cr..
• For Other Assets, as of Mar 2025, the value is 776.00 Cr.. The value appears strong and on an upward trend. It has increased from 730.00 Cr. (Mar 2024) to 776.00 Cr., marking an increase of 46.00 Cr..
• For Total Assets, as of Mar 2025, the value is 2,057.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,015.00 Cr. (Mar 2024) to 2,057.00 Cr., marking an increase of 42.00 Cr..

Notably, the Reserves (1,595.00 Cr.) exceed the Borrowings (10.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for NOCIL Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 6.17. This value is within the healthy range. It has decreased from 7.98 (Mar 24) to 6.17, marking a decrease of 1.81.
• For Diluted EPS (Rs.), as of Mar 25, the value is 6.15. This value is within the healthy range. It has decreased from 7.95 (Mar 24) to 6.15, marking a decrease of 1.80.
• For Cash EPS (Rs.), as of Mar 25, the value is 9.37. This value is within the healthy range. It has decreased from 11.15 (Mar 24) to 9.37, marking a decrease of 1.78.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 105.51. It has increased from 101.92 (Mar 24) to 105.51, marking an increase of 3.59.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 105.51. It has increased from 101.92 (Mar 24) to 105.51, marking an increase of 3.59.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 83.38. It has decreased from 86.69 (Mar 24) to 83.38, marking a decrease of 3.31.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 10.15. This value is within the healthy range. It has decreased from 14.07 (Mar 24) to 10.15, marking a decrease of 3.92.
• For PBIT / Share (Rs.), as of Mar 25, the value is 6.94. This value is within the healthy range. It has decreased from 10.90 (Mar 24) to 6.94, marking a decrease of 3.96.
• For PBT / Share (Rs.), as of Mar 25, the value is 6.83. This value is within the healthy range. It has decreased from 10.80 (Mar 24) to 6.83, marking a decrease of 3.97.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 6.16. This value is within the healthy range. It has decreased from 7.98 (Mar 24) to 6.16, marking a decrease of 1.82.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 6.16. This value is within the healthy range. It has decreased from 7.98 (Mar 24) to 6.16, marking a decrease of 1.82.
• For PBDIT Margin (%), as of Mar 25, the value is 12.17. This value is within the healthy range. It has decreased from 16.22 (Mar 24) to 12.17, marking a decrease of 4.05.
• For PBIT Margin (%), as of Mar 25, the value is 8.32. This value is below the healthy minimum of 10. It has decreased from 12.57 (Mar 24) to 8.32, marking a decrease of 4.25.
• For PBT Margin (%), as of Mar 25, the value is 8.19. This value is below the healthy minimum of 10. It has decreased from 12.45 (Mar 24) to 8.19, marking a decrease of 4.26.
• For Net Profit Margin (%), as of Mar 25, the value is 7.38. This value is within the healthy range. It has decreased from 9.20 (Mar 24) to 7.38, marking a decrease of 1.82.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 7.38. This value is below the healthy minimum of 8. It has decreased from 9.20 (Mar 24) to 7.38, marking a decrease of 1.82.
• For Return on Networth / Equity (%), as of Mar 25, the value is 5.83. This value is below the healthy minimum of 15. It has decreased from 7.83 (Mar 24) to 5.83, marking a decrease of 2.00.
• For Return on Capital Employeed (%), as of Mar 25, the value is 6.11. This value is below the healthy minimum of 10. It has decreased from 9.81 (Mar 24) to 6.11, marking a decrease of 3.70.
• For Return On Assets (%), as of Mar 25, the value is 5.00. This value is within the healthy range. It has decreased from 6.59 (Mar 24) to 5.00, marking a decrease of 1.59.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.68. It has decreased from 0.74 (Mar 24) to 0.68, marking a decrease of 0.06.
• For Current Ratio (X), as of Mar 25, the value is 5.82. This value exceeds the healthy maximum of 3. It has decreased from 5.89 (Mar 24) to 5.82, marking a decrease of 0.07.
• For Quick Ratio (X), as of Mar 25, the value is 4.07. This value exceeds the healthy maximum of 2. It has decreased from 4.55 (Mar 24) to 4.07, marking a decrease of 0.48.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.17. This value is below the healthy minimum of 4. It has increased from 3.08 (Mar 24) to 3.17, marking an increase of 0.09.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 37.58 (Mar 24) to 0.00, marking a decrease of 37.58.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 26.90 (Mar 24) to 0.00, marking a decrease of 26.90.
• For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 62.42 (Mar 24) to 0.00, marking a decrease of 62.42.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 73.10 (Mar 24) to 0.00, marking a decrease of 73.10.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 94.70. This value is within the healthy range. It has decreased from 144.69 (Mar 24) to 94.70, marking a decrease of 49.99.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 58.46. This value is within the healthy range. It has decreased from 83.10 (Mar 24) to 58.46, marking a decrease of 24.64.
• For Enterprise Value (Cr.), as of Mar 25, the value is 2,887.72. It has decreased from 4,059.04 (Mar 24) to 2,887.72, marking a decrease of 1,171.32.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.07. This value is within the healthy range. It has decreased from 2.81 (Mar 24) to 2.07, marking a decrease of 0.74.
• For EV / EBITDA (X), as of Mar 25, the value is 17.04. This value exceeds the healthy maximum of 15. It has decreased from 17.32 (Mar 24) to 17.04, marking a decrease of 0.28.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.10. This value is within the healthy range. It has decreased from 2.88 (Mar 24) to 2.10, marking a decrease of 0.78.
• For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 62.41 (Mar 24) to 0.00, marking a decrease of 62.41.
• For Price / BV (X), as of Mar 25, the value is 1.66. This value is within the healthy range. It has decreased from 2.45 (Mar 24) to 1.66, marking a decrease of 0.79.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.10. This value is within the healthy range. It has decreased from 2.88 (Mar 24) to 2.10, marking a decrease of 0.78.
• For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.03.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness